All In Biotech

Drug Trial Radar · NCT06268860

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

A Phase 1 Open-label, Randomized, Parallel-group Study to Assess the Relative Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

Feb 15, 2024

Primary completion

Aug 30, 2024

Study completion Oct 8, 2024

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.

Conditions

  • Atopic Dermatitis

Interventions

  • Rocatinlimab vial injectionDrug

    Vial solution for SC injection administered on Day 1

  • Rocatinlimab prefilled syringeCombination product

    Prefilled syringe solution for SC injection administered on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Serum Concentration (Cmax) of RocatinlimabTime frame: At predose on Day 1 and postdose on Day 1 through Day 112
  2. Area Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of RocatinlimabTime frame: At predose on Day 1 and postdose on Days 1 through Day 112
  3. AUC From Time Zero to Infinity (AUCinf) of RocatinlimabTime frame: At predose on Day 1 and postdose on Days 1 through Day 112

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit - Daytona Beach

    Daytona Beach, Florida

  • Fortrea Clinical Research Unit - Dallas

    Dallas, Texas

  • Fortrea Clinical Research Unit Inc. - Madison

    Madison, Wisconsin

  • Fortrea Clinical Research Unit Limited - Leeds

    Leeds, LDS, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.